Outset Medical, Inc. OM
We take great care to ensure that the data presented and summarized in this overview for Outset Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OM
View all-
Black Rock Inc. New York, NY880KShares$15.5 Million0.0% of portfolio
-
Birchview Capital, LP Burlington, VT24.6KShares$432,6780.24% of portfolio
-
Aton Ra Partners Geneva, V820.2KShares$355,7660.22% of portfolio
-
Brinker Capital Investments, LLC19.5KShares$343,4990.01% of portfolio
-
Alpha Paradigm Partners, LLC Chicago, IL14.5KShares$255,1120.16% of portfolio
-
Perpetual Investment Management LTD Sydney, C311.5KShares$203,0330.04% of portfolio
-
Fieldpoint Private Securities, LLC1.45KShares$25,5370.01% of portfolio
-
Ahrens Investment Partners LLC150Shares$2,6400.0% of portfolio
-
Wipfli Financial Advisors Llc,104Shares$1,8300.0% of portfolio
-
American Portfolios Advisors Holbrook, NY50Shares$8800.0% of portfolio
Latest Institutional Activity in OM
Top Purchases
Top Sells
About OM
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Insider Transactions at OM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2025
|
Marc Nash SVP Operations and R&D |
BUY
Grant, award, or other acquisition
|
Direct |
29,676
+40.75%
|
-
|
|
Jun 10
2025
|
Renee Gaeta Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
131,425
+50.0%
|
-
|
|
Jun 10
2025
|
Leslie Trigg Chair and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
65,103
+34.57%
|
-
|
|
Jun 10
2025
|
John L. Brottem General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
35,993
+43.23%
|
-
|
|
Jun 02
2025
|
Andrea Lynn Saia Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,983
+42.46%
|
-
|
|
Jun 02
2025
|
Patrick T Hackett Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,983
+8.62%
|
-
|
|
Jun 02
2025
|
Brent D. Lang Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,983
+33.48%
|
-
|
|
Jun 02
2025
|
Kevin C Oboyle Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,983
+27.14%
|
-
|
|
Jun 02
2025
|
Karen Drexler Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,983
+42.41%
|
-
|
|
Jun 02
2025
|
D Keith Grossman Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,983
+39.23%
|
-
|
|
May 15
2025
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
584
-3.5%
|
$9,928
$17.81 P/Share
|
|
May 15
2025
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
396
-3.39%
|
$6,732
$17.82 P/Share
|
|
May 15
2025
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
252
-1.84%
|
$4,284
$17.82 P/Share
|
|
May 15
2025
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
935
-1.58%
|
$15,895
$17.8 P/Share
|
|
May 14
2025
|
Kevin C Oboyle Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,135
+50.0%
|
-
|
|
Mar 10
2025
|
Leslie Trigg Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
625,000
+50.0%
|
-
|
|
Mar 10
2025
|
Karen Drexler Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
31,250
+50.0%
|
-
|
|
Mar 10
2025
|
Brent D. Lang Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
250,000
+50.0%
|
-
|
|
Mar 10
2025
|
D Keith Grossman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
187,500
+49.32%
|
-
|
|
Mar 10
2025
|
Patrick T Hackett Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,875,000
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 459K shares |
|---|---|
| Exercise of conversion of derivative security | 4.22M shares |
| Open market or private sale | 332K shares |
|---|